Mitochondrial & sleep · Research tetrapeptide

Epitalon

Also known as AEDG peptide, Ala-Glu-Asp-Gly, Epithalon

A defined four-amino-acid peptide discussed mainly in ageing-related laboratory and animal research. It is not an FDA-approved drug.[1]

Compare

Prepare questions

Published evidenceMostly preclinical evidence

The evidence is mainly from cells, tissues, or animals. Any human information is limited or indirect and does not establish a clinical outcome.

U.S. status: No FDA-approved product identified
Published context: Energy, sleep and healthy-aging research
Form and route: Identity-scoped epitalon research material · Not separately published
Main uncertainty: Clinical pharmacology, effectiveness, long-term safety, reproducibility, and the relevance of biomarker or animal findings are unresolved. Absence of adequate trials is not evidence of either benefit or no biological activity.

Reviewed Jul 22, 2026 · U.S.-focused reference profile

Read the context, not only the compound name. Evidence and status can change with the form, route, population, and use. This profile does not assess individual suitability.

Orientation

What this is

Start with identity and research context. Similar names do not establish equivalent products or evidence.

Published name: Epitalon
Type: Research tetrapeptide
Primary topic: Mitochondrial, neurological, and sleep research
Aliases: AEDG peptide, Ala-Glu-Asp-Gly, Epithalon

Where it has been studied or used

Published research or product contexts. These are not personal indications.

Energy, sleep and healthy-aging research

Why exact identity matters

Evidence can change with chemical form, formulation, route, ingredients, and manufacturing. A brand, salt, fragment, or cosmetic ingredient may not represent the same evidence.

What is known

Evidence, in context

Overall published evidenceMostly laboratory or animal evidence

The evidence is mainly from cells, tissues, or animals. Any human information is limited or indirect and does not establish a clinical outcome. This is a description, not a rating or recommendation.

Energy, sleep and healthy-aging research

Published human evidence context

Preclinical evidence

FDA found no human study establishing effectiveness for insomnia or another proposed clinical use. A small sublingual biomarker study did not establish a patient benefit, and FDA found no adequate human safety data.

Limits and source

Clinical pharmacology, effectiveness, long-term safety, reproducibility, and the relevance of biomarker or animal findings are unresolved. Absence of adequate trials is not evidence of either benefit or no biological activity.

Epitalon

What this is

Where it has been studied or used

Evidence, in context

Published human evidence context

Risks and unknowns

Published risk information

What remains uncertain

Forms and routes

Identity-scoped epitalon research material

U.S. status

Research only

Questions worth discussing

Sources and methodology